BASEL, Switzerland (PRWEB)
September 11, 2019

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D in the areas of oncology, the central nervous system, and other medical indications.

“As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes,” said Tim Holmström, Head of Biologics at Orion Pharma. “Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization. Also, collaborating with CROs is a key part of our strategy, so we require an open and scalable system able to capture and integrate all data generated by our CRO network. Finally, Genedata’s offering of Software-as-a-Service (SaaS) was an additional plus because we wanted a self-maintaining model that provides regular upgrades of new, innovative functionalities.”

Genedata Biologics enables Orion scientists to easily capture, process, and interpret all large-molecule R&D data and facilitate the design of antibodies. Further, it integrates all assay and analytics data to enable a comprehensive assessment of all drug candidates. The platform helps eliminate error-prone manual processes by providing a robust, standardized data repository that can be integrated with laboratory instrumentation. All molecule, sample, assay and analytics data, including developability and manufacturability data, are managed within one fully integrated system and are shared between different project teams and sites. The platform facilitates systematic and transparent decision-making to select drug candidates to be progressed through the development pipeline.

“We are very pleased that Orion, an innovative R&D-based pharmaceutical company, has selected Genedata Biologics as their workhorse platform for their biopharma R&D operations. By providing Orion with a backbone that covers their entire discovery pipeline in a single system, we help to increase the efficiency of their R&D processes and speed up decision making,” said Dr. Othmar Pfannes, CEO of Genedata. “Our technology, combined with Orion’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

http://www.genedata.com

Follow Us on LinkedIn.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

WASHINGTON (PRWEB)
August 22, 2019

With jobs in forensic science expected to increase by nearly 20 percent by 2026, four U.S. universities now have STRmix™ – sophisticated forensic software that can resolve mixed DNA profiles previously thought to be too complex to interpret – as a planned or existing component of their student coursework.

The universities include: California State University, Sacramento; Eastern Kentucky University; George Washington University (GWU); and Marshall University (Graduate Program). They join two other universities, both in Canada, with STRmix™ in North America. Of interest, GWU plan to use STRmix™ in teaching a class in which students will be performing an internal validation of STRmix™ that will be the essential core of the class.

“With interest in forensic science careers on the rise, thanks in part to TV shows like CSI, it is only natural for universities to want to provide students with the ability to work in their labs with the same kind of forensic software they are likely to find themselves using in the workplace,” says John Buckleton DSc, FRSNZ, Forensic Scientist at the New Zealand Institute of Environmental Science and Research (ESR) and one of the developers of STRmix™.

According to the U.S. Bureau of Labor Statistics, employment of forensic science technicians is projected to grow 17 percent from 2016-2026, much faster than average for all occupations. Because the sector remains relatively small, however, competition for those jobs is expected to be very strong.

Beyond the universities, STRmix™ is now being used by the forensic labs of 46 U.S. agencies. That list includes federal agencies like the FBI and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), state agencies such as those recently added in Massachusetts, South Carolina, and Colorado, and private companies like Bode Cellmark Forensics.

STRmix™ is also in various stages of installation, validation, and training in more than 60 other U.S. labs.

Dr. Buckleton attributes the widespread use of STRmix™ to its ability to significantly improve the usability of DNA. “More and more forensic labs worldwide are turning to STRmix™ to produce usable DNA evidence in a wide range of criminal cases,” he explains, noting that agencies using STRmix™ are reporting an increase of interpretable DNA in gun cases from about 40% to more than 70%. STRmix™ is also proving to be highly effective in sexual assault cases.

“Given the considerable resources invested in both resources and staff time to clear Sexual Assault Kit backlogs, forensic labs are quickly recognizing that STRmix™ is producing a much better return on investment by delivering a significantly higher rate of interpretable results,” Dr. Buckleton adds.

To date, STRmix™ has been used successfully in numerous U.S. court cases, including 28 successful admissibility hearings. Internationally, STRmix™ has been used to interpret DNA evidence in more than 120,000 cases since 2012.

STRmix™ is also being used in all nine state and territory labs in Australia and New Zealand, as well as 12 forensic labs in England, Scotland, Ireland, Finland, Dubai, Denmark, and Canada.

For more information about STRmix™ visit http://www.strmix.com.

Share article on social media or email:

NASHVILLE, Tenn. (PRWEB)
August 29, 2019

The Upper Room recently released a workbook edition of A Spirituality of Fundraising by Henri J. M. Nouwen and Nathan Ball. Nouwen, a best-selling spiritual writer and renowned scholar, innovated the way church and nonprofit leaders view fundraising in his original book, A Spirituality of Fundraising. This book changed tthe way people look at fundraising—from viewing it as a fear- and scarcity-driven task to seeing it as a spiritual journey. Nouwen writes, “Fundraising, first and foremost, is a form of ministry. It is a way of announcing our vision and inviting other people into our mission.”

Inspired by Nouwen’s vision, The Upper Room sought the expertise of Nouwen’s close friend and colleague Nathan Ball, asking him to write an accompanying workbook to aid fundraisers as they seek practical applications to Nouwen’s culture-shifting vision.

Ball, who met and shared community life with Henri Nouwen for over 10 years in Jean Vanier’s L’Arche communities in France and Canada, has more than 20 years of experience in fundraising-related roles.

“You may not have imagined that the task of fundraising would take you into a deeper relationship with yourself and God,” Ball writes. “You are embarking on a beautiful, Spirit-filled journey. Be grateful that you have Henri as your trustworthy guide. Give thanks for who you are, and embrace this journey in a wholehearted way.”

In A Spirituality of Fundraising Workbook Edition, Ball tackles the trepidations of fundraisers head-on with a 4-week how-to guide that includes questions for reflection and journaling, prompts for listening and meditation, and instructions for using the book in individual or group settings.

Nouwen and Ball invite all fundraisers—from church leaders to nonprofit volunteers—to embrace fundraising as a ministry and calling. Learn more about the workbook at UpperRoomBooks.com/FundraisingWorkbook.

About The Upper Room: The Upper Room is a global ministry dedicated to supporting the spiritual formation of Christians seeking to know and experience God more fully. From its beginnings in 1935 as a daily devotional guide, The Upper Room has grown to include publications, programs, prayer support, and other resources to help believers of all ages and denominations move to a deeper level of faith and service. To learn more, visit UpperRoom.org.

Share article on social media or email:

BASEL, Switzerland (PRWEB)
September 11, 2019

The partnership between Clinerion and Volv Global brings benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s growing data network of hospitals around the world. The Volv and Clinerion partnership will deploy Volv’s inTrigue algorithms across many more hospitals and this will create tangible outcomes for patients who suffer from late diagnosis of between seven and 15 years, as well as from misdiagnosis and subsequent increased disease burden.

Volv’s inTrigue toolset offers enhanced clinical trial cohort selection and patient modeling for earlier diagnosis of rare and difficult to diagnose diseases. This supports rare disease communities who wish to be able to deploy effective early diagnostic signaling tools to help patients get earlier referral and confirmatory diagnosis.

Clinerion’s Patient Network Explorer leverages patient electronic health record (EHR) data to offer data intelligence for the acceleration of drug development, bringing innovative drugs earlier to patients. PNEx performs real-time patient data analytics on electronic medical records from Clinerion’s network of connected hospitals to offer solutions for clinical trial patient recruitment and generate data for real-world evidence. This process accelerates recruitment, the most prominent reason for trial delays, which result in avoidable suffering of patients and cost pharmaceutical companies sales revenues.

“Our partnership brings direct benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s rapidly growing data network of hospitals around the world,“ says Christopher Rudolf, CEO of Volv. “We can jointly offer a wider reach for earlier diagnosis of rare diseases and enhanced clinical trial cohort selection through the inTrigue toolset and Clinerion’s PNEx.”

“AI integration is the next crucial step in the development of Patient Network Explorer,” says Ian Rentsch, Clinerion CEO. “Volv’s technologies will support us in harnessing the full power of the patient data in our hospital partners’ databases, to the betterment of patient outcomes throughout our network.”

Clinerion and Volv Global will launch their partnership at a special event at the Intelligent Health AI conference on September 11th-12th, in Basel, Switzerland. Please contact the press officers below if you would like to interview representatives of the two companies.

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion Website: http://www.clinerion.com

Clinerion’s Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:

Le Vin Chin

Director, Head of Marketing & Communications

Clinerion Ltd

Elisabethenanlage 11, 4051 Basel, Switzerland

Tel.: +41 61 865 60 54

media(at)clinerion(dot)com

About Volv Global SA

Volv is a Swiss is an AI and applied data science company based in Lausanne that produces solutions to address key critical issues in Healthcare for today and tomorrow. We develop differentiated Artificial Intelligence methodologies addressing a defined set of problems in healthcare, and have solutions that are targeted on rare diseases, personalised medicines and difficult-to-diagnose diseases with the product inTrigue. We also focus on cognitive disorders with inCognita, and are working on breakthrough management solutions for anti-microbial resistance and personalised oncology.

With unique tools, including some that are focused on finding weak signals in sparse, unstructured and structured data, Volv has a unique position in the Artificial Intelligence landscape. This allows us to focus on tangible economic and healthcare outcomes by differentiating patient cohorts and symptoms in a novel way that is required for the next generation of healthcare and the change in population dynamics that we see evolving. Volv’s toolsets are repeatable solutions that can fit into any data environment and allow rapid return on investment for our customers, building to longer term strategic partnerships.

Volv Global website: http://www.volv.global

For more information, please contact:

Jan Prins

Business Officer

Volv Global SA, Digital Health Hub, Building SE-A, Route de la Corniche 3, 1066 Epalinges, Switzerland

Tel.: +41 79 739 37 05

jprins(at)volv(dot)global

Share article on social media or email:

ISELIN, N.J. (PRWEB)
September 05, 2019

Early childhood education franchise Lightbridge Academy has been incorporating sign language into its curriculum for children as young as six weeks old for nearly 20 years. Now, Lightbridge Academy is expanding its industry-leading sign language learning program with a library of new video modules for parents to extend the learning and use of sign language beyond its centers and into the home.

“The Signing Sprouts program has existed almost as long as Lightbridge Academy,” said VP of Education and Training Jennifer Romanoff. “Infants are looking to communicate, though they can’t yet articulate. This manifests in crying, or some other form of frustration. In an effort to mitigate that, we began analyzing infant sign language studies and eventually started implementing it into what we do.”

In addition, sign language also helps to ensure that children on a proven pathway to early literacy and cognitive learning. As such early adopters of the science, it’s no wonder Lightbridge Academy leads the industry in teaching sign language to children and their families. The practice of including parents in their efforts helps to extend learning and create a home and school connection as well.

“We really see it as an enhancement,” Romanoff said. “It lowers infant frustration and helps them communicate before palate development occurs. We start introducing sign language to children as young as six weeks old with ‘more,’ ‘eat,’ and ‘please’ signs. If exposed on a regular basis, we start seeing a response in the children somewhere around nine months old.”

Lightbridge Academy’s sign language program expands when children reach the mobile infant stage of development and again at the preschool and pre-K age group, when the American Sign Language (ASL) alphabet, colors, animals and more are incorporated into their daily curriculum.

While the brand has always had supplemental resources for parents, the Lightbridge Academy team sees the rollout of its new video resource library as an opportunity to take its sign language program to the next level.

The interactive modules feature ASL-certified Lightbridge Academy instructor Sydnie Burnett and are available to all parents via the Lightbridge Academy e-communication tool or YouTube channel. The video resource library was launched with a threefold series: the Top 10 Signs to Use with Infants, the Top 10 Signs to Use with Toddlers and the Top 10 Signs to Use with Pre-K Students. The library’s curriculum will match the thematic units that children are learning at any given time.

Burnett, who has been a Lightbridge Academy instructor for four and a half years, was introduced to ASL while in high school, but didn’t fall in love with the language until college. As a visual learner, she found it to be a more interactive way to communicate and ended up minoring in ASL.

“Children learn a lot more through sign because they can see something, replicate it and understand the meaning,” Burnett said. “It’s their way of communicating without verbal cues. The fact that ASL is already implemented in the Lightbridge curriculum is so beneficial to students, their families and our staff because it equips kids with a language they don’t have yet, not verbal, but visual. These modules will help change the perspective of how kids learn.”

“As a culture, we speak with our hands already,” Romanoff said. “Now, we’re doing that with intention. ASL gives parents and educators a universal language to communicate with young children. The videos are the perfect at-home parent resource to use when reinforcing the signs children are learning in school and with technology, these tools are readily accessible. It is so exciting to hear back from parents when they see a change in their baby from screaming in frustration to understanding how to connect by using a sign for “more”. This program helps to create the school-to-home connection between parents and educators that creates the trusting bonds necessary for development, learning and importantly, a sense of well-being.”

About Lightbridge Academy:

Established in 1997, Lightbridge Academy provides early education and child care to children ages six weeks through kindergarten, as well as special programming for children up to 10 years old during school holidays, breaks and summer camp. The company franchised in 2011 in an effort to expand their distinctive concept throughout the Northeast; it currently has over 100 child care centers either open, under construction or in development throughout Florida, Maryland, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Virginia. Guy and Julia Falzarano founded the company based on core values and a Circle of Care philosophy that places equal importance on the needs of children, their families, teachers, center owners, and the community. In 2019, Lightbridge Academy was ranked on Entrepreneur Magazine’s Franchise 500, and it was featured on the Franchise Times Top 200+ in 2018. To learn more about Lightbridge Academy, prospective families and franchisees are encouraged to visit http://www.LightbridgeAcademy.com or call (732) 980-1900 x 199.

Share article on social media or email: